REPR -- profitable, cash-rich, rapidly growing, recession-proof, tiny float OS & market cap with a juicy FDA approval pending any week...
Management is so confident of continued much higher profits than last quarter going forward that they have set aside a "deferred tax asset" in the balance sheet "based the valuation allowance calculations on the prospect of future profitability" http://pinksheets.com/edgar/GetFilingHtml?FilingID=6632631
Based on seasonal & cylical patterns as well as their recent hiring and doubling of shifts and landing business with a huge hospital & the pending FDA approval, I suspect REPR is 1 or 2 quarters away from +.02 EPS per quarter or more or an annualized +.08 EPS pace IMO. 10 PE = .80/share, 15 PE = $1.20/share. 20 PE = $1.80/share
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.